Àç»ý ÀÇ·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Çü, Á¦Ç°, ¼­ºñ½º, ±â¼ú, ¿ëµµ, Àç·á À¯Çü, ÇÁ·Î¼¼½º, ÃÖÁ¾ »ç¿ëÀÚ, µð¹ÙÀ̽ºº°(-2033³â)
Regenerative Medicine Market Analysis and Forecast to 2033: Type, Product, Services, Technology, Application, Material Type, Process, End User, Device
»óǰÄÚµå : 1632997
¸®¼­Ä¡»ç : Global Insight Services LLC
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 368 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,798,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,229,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,660,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àç»ý ÀÇ·á ½ÃÀåÀº 2023³â 189¾ï ´Þ·¯¿¡¼­ 2033³â 1,262¾ï ´Þ·¯·Î È®´ëµÇ¾úÀ¸¸ç, CAGRÀº 21.2%°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àç»ý ÀÇ·á ½ÃÀåÀº Àΰ£ÀÇ ¼¼Æ÷, Á¶Á÷, ±â°üÀ» ¼ö¸®, ´ëü, Àç»ýÇÏ¿© Á¤»óÀûÀÎ ±â´ÉÀ» ȸº¹½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ °³¹ß°ú ÀÀ¿ëÀ» Æ÷ÇÔÇÕ´Ï´Ù. Áٱ⠼¼Æ÷ Ä¡·á, Á¶Á÷ °øÇÐ, À¯ÀüÀÚ Ä¡·á, »ýü Àç·á µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀåÀº ÅðÇ༺ Áúȯ, ¿Ü»ó, ¼±Ãµ¼º Àå¾Ö¿Í °°Àº Áõ»ó¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ÃæÁ·µÇÁö ¾ÊÀº ÀÇ·á ¿ä±¸¿¡ ´ëÀÀÇϰí ÀÇ·á ¹× ¸ÂÃãÇü ÀÇ·á¿¡¼­ ÆÐ·¯´ÙÀÓ À̵¿À» ¾à¼ÓÇÕ´Ï´Ù.

Àç»ý ÀÇ·á ½ÃÀåÀº Áٱ⠼¼Æ÷ Ä¡·á¿Í Á¶Á÷ °øÇÐÀÇ Áøº¸·Î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. Áٱ⠼¼Æ÷ Ä¡·á, ƯÈ÷ ÀÚ±â Áٱ⠼¼Æ÷ Ä¡·á¿Í µ¿Á¾ Áٱ⠼¼Æ÷ Ä¡·á°¡ ½ÃÀåÀ» ¼±µµÇÏ°í ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡ º¯È­ÀÇ °¡´É¼ºÀ» °¡Á®¿Ô½À´Ï´Ù. Á¶Á÷ °øÇÐÀº Àå±â À̽İú »óó Ä¡À¯¿¡ÀÇ ÀÀ¿ë¿¡ ÀÇÇØ °ßÀηÂÀ» ´Ã¸®°í ÀÖÀ¸¸ç, 2À§ ½ÃÀå ±Ô¸ð¸¦ ÀÚ¶ûÇÏ´Â ÇÏÀ§ ºÎ¹®ÀÔ´Ï´Ù. À¯ÀüÀÚ Ä¡·á´Â Ä¡·á È¿°ú¸¦ ³ôÀÌ´Â ±â¼ú Çõ½ÅÀ¸·Î Áß¿äÇÑ ¿ä¼Ò°¡µÇ°í ÀÖ½À´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ¾î ¿¬±¸°³¹ß¿¡ÀÇ ´Ù¾×ÀÇ ÅõÀÚ¿Í À¯¸®ÇÑ ±ÔÁ¦ ƲÀÌ ±× ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·± ´ÙÀ½ À¯·´Àº ±â¼ú Áøº¸¿Í Àç»ý ÀÇ·á ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø¿¡ ÁßÁ¡À» µÓ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÇコÄɾî ÁöÃâ Áõ°¡, »ý¸í°øÇÐ ºÎ¹®ÀÇ ±Þ¼ºÀå, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥¿¡ °ßÀÎµÇ¾î ±Þ¼ÓÈ÷ °¢±¤À» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ¿ªµ¿Àû ÀÎ »óȲÀº Çõ½ÅÀûÀÌ°í °³ÀÎÈ­µÈ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌÇØ °ü°èÀÚ¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

2023³â ½ÃÀå ±Ô¸ð´Â 3¾ï À¯´ÖÀ¸·Î °ßÁ¶Çϸç 2033³â¿¡´Â 5¾ï À¯´Ö±îÁö È®´ëÇÒ Àü¸ÁÀÔ´Ï´Ù. ½ÃÀå Á¡À¯À²Àº Á¶Á÷ °øÇÐ ºÐ¾ß°¡ 45%·Î °¡Àå ³ô°í, À̾ ¼¼Æ÷ Ä¡·á°¡ 35%, À¯ÀüÀÚ Ä¡·á°¡ 20%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. Á¶Á÷ °øÇÐÀÇ ÀÌÁ¡Àº ¹ÙÀÌ¿À Àç·á ¹× ºñ°è ±â¼úÀÇ ¹ßÀü ¶§¹®ÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Organogenesis Holdings Inc., Acelity LP Inc., Integra LifeSciences Corporation µîÀÌ ÀÖÀ¸¸ç, °¢°¢ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷ÀÇ Àü·«Àû Á¦ÈÞ¿Í Á¦Ç° Çõ½ÅÀº °æÀï ±¸µµ¸¦ Å©°Ô Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

FDA Áöħ°ú EMA ÁöħÀ¸·Î ´ëÇ¥µÇ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ ¿öÅ©´Â ƯÈ÷ ½ÂÀÎ ÀÏÁ¤ ¹× ±ÔÁ¤ Áؼö ºñ¿ë Ãø¸é¿¡¼­ ½ÃÀå ¿ªÇп¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ ºÐ¾ß°¡ ¹ßÀüÇÔ¿¡ µû¶ó ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¿Í Àü·«Àû M&A°¡ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. Àç»ý ÀÇ·áÀÇ Àü¸ÁÀº ¿©ÀüÈ÷ ³«°üÀûÀ̸ç À¯ÀüÀÚ Ä¡·á ±âȸ°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú °³¹ß ºñ¿ëÀÌ ³ô´Ù´Â ¹®Á¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù. Àç»ý ÀÇ·á ¿¬±¸¿¡¼­ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº »õ·Î¿î ¼ºÀåÀÇ ±æÀ» ¿­ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â Àç»ý ÀÇ·á ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÁöÀ§´Â °ß°íÇÑ R&D Ȱµ¿¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº Çõ½ÅÀûÀÎ Ä¡·á¹ý°ú ±â¼ú¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ±â°üÀÇ °­·ÂÇÑ Áö¿øÀº ¼ºÀå Àü¸ÁÀ» ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ¹ÙÀÌ¿À ÀǾàǰ ±â¾÷ÀÇ Á¸Àç°¡ °æÀï ȯ°æÀ» Á¶¼ºÇϰí Áøº¸¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

À¯·´Àº µ¶Àϰú ¿µ±¹°ú °°Àº ±¹°¡µéÀÌ ÃÖÀü¼±¿¡ ÀÖÀ¸¸ç, ±× µÚ¸¦ À̾ú½À´Ï´Ù. ÀÌ ³ª¶óµéÀº °Ç°­ °ü¸® Çõ½Å°ú ±ÔÁ¦ Ãø¸é¿¡ ´ëÇÑ Áö¿øÀ» ¼±È£ÇÕ´Ï´Ù. EU´Â ÷´Ü ÀÇ·á ¼Ö·ç¼ÇÀ» Áß½ÃÇϰí ÀÖÀ¸¸ç ½ÃÀå È®´ë¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù. Çмú±â°ü°ú ¾÷°è °ü°èÀÚÀÇ Çù·Â üÁ¦µµ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. Áß±¹°ú ÀϺ» µîÀÇ ±¹°¡µéÀº ÀÌ ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í À¯¸®ÇÑ Á¤Ã¥Àº Àç»ý Ä¡·áÀÇ °³¹ßÀ» Áö¿øÇÕ´Ï´Ù. ¸¸¼º ÁúȯÀÇ ¸¸¿¬ÀÌ ´õ¿í ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ½ÅÈï ½ÃÀåÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â Àç»ý ÀÇ·á°¡ Á¡Â÷ µµÀԵǰí ÀÖ½À´Ï´Ù. ÀÎÁöµµ Çâ»ó°ú ÀÇ·á ÀÎÇÁ¶ó °³¼±ÀÌ Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ±×·¯³ª Á¦ÇÑµÈ Àڱݰú ±ÔÁ¦ Àå¾Ö¹°°ú °°Àº °úÁ¦µµ ³²¾Æ ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ¾ÕÀ¸·Î ¼ö³â°£ÀÇ ¼ºÀå °¡´É¼ºÀº Å®´Ï´Ù.

¸ñÂ÷

Á¦1Àå Àç»ý ÀÇ·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ Áß¿ä ÀλçÀÌÆ®

Á¦4Àå Àç»ý ÀÇ·á ½ÃÀå Àü¸Á

Á¦5Àå Àç»ý ÀÇ·á ½ÃÀå Àü·«

Á¦6Àå Àç»ý ÀÇ·á ½ÃÀå ±Ô¸ð

Á¦7Àå Àç»ý ÀÇ·á ½ÃÀå : À¯Çüº°

Á¦8Àå Àç»ý ÀÇ·á ½ÃÀå : Á¦Ç°º°

Á¦9Àå Àç»ý ÀÇ·á ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå Àç»ý ÀÇ·á ½ÃÀå : ±â¼úº°

Á¦11Àå Àç»ý ÀÇ·á ½ÃÀå : ¿ëµµº°

Á¦12Àå Àç»ý ÀÇ·á ½ÃÀå : Àç·á À¯Çüº°

Á¦13Àå Àç»ý ÀÇ·á ½ÃÀå : ÇÁ·Î¼¼½ºº°

Á¦14Àå Àç»ý ÀÇ·á ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦15Àå Àç»ý ÀÇ·á ½ÃÀå : µð¹ÙÀ̽ºº°

Á¦16Àå Àç»ýÀÇ·á½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The regenerative medicine market is expected to expand from $18.9 billion in 2023 to $126.2 billion by 2033, with a CAGR of 21.2%.

The Regenerative Medicine Market encompasses the development and application of innovative therapies aimed at repairing, replacing, or regenerating human cells, tissues, or organs to restore normal function. It includes stem cell therapy, tissue engineering, gene therapy, and biomaterials. This market addresses unmet medical needs by offering transformative solutions for conditions such as degenerative diseases, trauma, and congenital disorders, promising a paradigm shift in healthcare and personalized medicine.

The regenerative medicine market is witnessing robust growth, driven by advancements in stem cell therapy and tissue engineering. Stem cell therapy, particularly autologous and allogeneic stem cell treatments, leads the market, offering transformative potential in treating chronic diseases. Tissue engineering is the second-highest performing sub-segment, gaining traction due to its applications in organ transplantation and wound healing. Gene therapy is emerging as a vital component, with innovations enhancing its therapeutic efficacy. Regionally, North America dominates the market, fueled by substantial investments in research and development and favorable regulatory frameworks. Europe follows, with a strong emphasis on technological advancements and government support for regenerative medicine initiatives. The Asia-Pacific region is rapidly gaining prominence, driven by increasing healthcare expenditure, a burgeoning biotechnology sector, and supportive government policies. This dynamic landscape presents lucrative opportunities for stakeholders to capitalize on the growing demand for innovative and personalized medical solutions.

In 2023, the market exhibited a robust volume of 300 million units, with expectations to escalate to 500 million units by 2033. The tissue engineering segment commands the largest market share at 45%, followed by cell therapy at 35%, and gene therapy at 20%. The dominance of tissue engineering is driven by advancements in biomaterials and scaffold technology. Key players in the market include Organogenesis Holdings Inc., Acelity L.P. Inc., and Integra LifeSciences Corporation, each holding substantial market shares. These companies' strategic alliances and product innovations significantly shape the competitive landscape.

The regulatory framework, highlighted by FDA guidelines and EMA directives, significantly impacts market dynamics, particularly in terms of approval timelines and compliance costs. As the sector evolves, investment in research and development, coupled with strategic mergers and acquisitions, will be critical. The outlook for regenerative medicine remains optimistic, with burgeoning opportunities in gene therapy. Nevertheless, challenges such as regulatory hurdles and high development costs persist. The integration of AI and machine learning in regenerative medicine research is anticipated to open new growth avenues.

North America dominates the regenerative medicine market. This position is driven by robust research and development activities. The United States, in particular, invests heavily in innovative therapies and technologies. Strong support from governmental bodies further enhances growth prospects. Additionally, the presence of leading biopharmaceutical companies fosters a competitive environment, accelerating advancements.

Europe follows closely, with countries like Germany and the United Kingdom at the forefront. These nations prioritize healthcare innovation and regulatory support. The European Union's emphasis on advanced healthcare solutions propels market expansion. Collaborative efforts between academic institutions and industry players also play a pivotal role.

Asia Pacific is experiencing rapid growth. The region benefits from increasing investments in healthcare infrastructure. Countries such as China and Japan are key contributors to this expansion. Government initiatives and favorable policies support the development of regenerative therapies. The growing prevalence of chronic diseases further drives demand.

Latin America and the Middle East & Africa are emerging markets. These regions are witnessing gradual adoption of regenerative medicine. Increasing awareness and improving healthcare infrastructure are crucial factors. However, challenges remain, such as limited funding and regulatory hurdles. Despite these, the potential for growth is significant in the coming years.

Key Companies

Mesoblast, Athersys, Pluristem Therapeutics, Cytori Therapeutics, Osiris Therapeutics, Organogenesis, Stem Cells, Ti Genix, Vericel, Re Neuron, Ocata Therapeutics, Bio Time, Histogenics, Blue Rock Therapeutics, Gamida Cell, Cynata Therapeutics, Axo Gen, Sangamo Therapeutics, Fate Therapeutics, Cellular Dynamics International

Sources

National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), International Society for Stem Cell Research (ISSCR), World Health Organization (WHO), International Society for Cell & Gene Therapy (ISCT), National Institute for Health and Care Excellence (NICE), Japan Agency for Medical Research and Development (AMED), Australian Regenerative Medicine Institute (ARMI), Harvard Stem Cell Institute, Stanford Institute for Stem Cell Biology and Regenerative Medicine, California Institute for Regenerative Medicine (CIRM), European Society of Gene and Cell Therapy (ESGCT), Alliance for Regenerative Medicine (ARM), Regenerative Medicine Foundation, World Stem Cell Summit, International Conference on Tissue Engineering and Regenerative Medicine, TERMIS (Tissue Engineering and Regenerative Medicine International Society) World Congress, International Conference on Regenerative Medicine, International Conference on Stem Cells and Regenerative Medicine

Research Scope

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Regenerative Medicine Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Regenerative Medicine Market Outlook

5: Regenerative Medicine Market Strategy

6: Regenerative Medicine Market Size

7: Regenerative Medicine Market, by Type

8: Regenerative Medicine Market, by Product

9: Regenerative Medicine Market, by Services

10: Regenerative Medicine Market, by Technology

11: Regenerative Medicine Market, by Application

12: Regenerative Medicine Market, by Material Type

13: Regenerative Medicine Market, by Process

14: Regenerative Medicine Market, by End User

15: Regenerative Medicine Market, by Device

16: Regenerative Medicine Market, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â